Full Product Name
CFC1 siRNA (Mouse)
Product Synonym Names
Cryptic protein
Product Gene Name
CFC1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P97766
Specificity
CFC1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CFC1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CFC1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CFC1 sirna
siRNA to inhibit CFC1 expression using RNA interference
Applications Tested/Suitable for CFC1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CFC1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_031711.1
[Other Products]
NCBI GenBank Nucleotide #
NM_007685.2
[Other Products]
UniProt Primary Accession #
P97766
[Other Products]
UniProt Secondary Accession #
Q496U5; Q9JIB7[Other Products]
UniProt Related Accession #
P97766[Other Products]
Molecular Weight
21,792 Da
NCBI Official Full Name
cryptic protein
NCBI Official Synonym Full Names
cripto, FRL-1, cryptic family 1
NCBI Official Symbol
Cfc1 [Similar Products]
NCBI Official Synonym Symbols
cryptic; AV265756; b2b970Clo
[Similar Products]
NCBI Protein Information
cryptic protein
UniProt Protein Name
Cryptic protein
Protein Family
Cryptic protein
UniProt Gene Name
Cfc1 [Similar Products]
UniProt Entry Name
CFC1_MOUSE
UniProt Comments for CFC1
CFC1: NODAL coreceptor involved in the correct establishment of the left-right axis. May play a role in mesoderm and/or neural patterning during gastrulation. Defects in CFC1 are the cause of visceral heterotaxy autosomal type 2 (HTX2). A form of visceral heterotaxy, a complex disorder due to disruption of the normal left-right asymmetry of the thoracoabdominal organs. It results in an abnormal arrangement of visceral organs, and a wide variety of congenital defects including cardiac malformations and situs inversus or situs ambiguus. Defects in CFC1 are a cause of transposition of the great arteries dextro-looped type 2 (DTGA2). A congenital heart defect consisting of complete inversion of the great vessels, so that the aorta incorrectly arises from the right ventricle and the pulmonary artery incorrectly arises from the left ventricle. This creates completely separate pulmonary and systemic circulatory systems, an arrangement that is incompatible with life. Patients often have atrial and/or ventricular septal defects or other types of shunting that allow some mixing between the circulations in order to support life minimally, but surgical intervention is always required. Defects in CFC1 are a cause of conotruncal heart malformations (CTHM). CTHM consist of cardiac outflow tract defects, such as tetralogy of Fallot, pulmonary atresia, double-outlet right ventricle, truncus arteriosus communis, and aortic arch anomalies.
Protein type: Membrane protein, GPI anchor
Cellular Component: membrane; plasma membrane; extracellular region
Biological Process: spleen development; heart morphogenesis; anatomical structure development; multicellular organismal development; digestive tract morphogenesis; gastrulation; Wnt receptor signaling pathway through beta-catenin; liver development; post-embryonic development; anterior/posterior pattern formation; BMP signaling pathway; heart looping; determination of left/right symmetry; endoderm development
Research Articles on CFC1
1. Functional redundancy of the Cfc1 gene in epiblast and extraembryonic patterning during early mouse embryogenesis is reported.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
